1. Personalized Medicine: Balancing the Promise and Peril of Pharmacogenomics Tamara Zemlo, Ph.D., MPH Executive Director The Science Advisory Board

3. Opportunities: Information Exchange Technology Needs Product Usage Emerging Trends Best Practices New Product Availability Technology Innovations Through the Internet, The Science Advisory Board facilitates this multilayer, bilateral communication effectively and efficiently. The Science Advisory Board Blogs Forum Posts Perspectives Product Reviews In-Depth Interviews Focus Groups Instant Polls Surveys Life Science Companies Scientists

8. Ethical Hotspots Economic Pandora Research Social Clinical

9. Economic Research Clinical Social Ethical Issues: Research

10. Research Issues Deciding on a Research Focus: • Single gene (i.e., easier to treat) • Polygenic diseases and/or disorders (i.e., harder to treat) Consequence: Potential to develop drugs for a specific genotype that are harmful to other genotypes

11. Research Issues Demonstrating Utility: Just because a mutation is associated with a specific disease does not mean its gene would make an effective drug target.

12. Research Issues • Narrower target population could exclude those who might also benefit from therapies • Evaluating therapies in smaller, targeted trials might miss critical, albeit rare, adverse drug events Translating

13. Economic Research Clinical Social Ethical Issues: Clinical

15. Clinical Issues Family History Pharmacogenomics Profile Manage Protect Create Confidentiality Privacy Patient Record Current Health Status

16. Economic Research Clinical Social Ethical Issues: Social

18. Social Issues Challenges: • Preventing discrimination: Insurance Jobs Educational opportunities • Legal implications: Regulation Enforcement Prosecution Restitution

20. Economic Clinical Research Social Ethical Issues: Economic